Lantheus Holdings, Inc. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Lantheus Holdings, Inc. (LNTH) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $637.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-26
- Lantheus Holdings, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for the quarter ending 2021-12-31 was -$200.00K.
- Lantheus Holdings, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for the quarter ending 2021-09-30 was $0.00.
- Lantheus Holdings, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for the quarter ending 2021-06-30 was $200.00K.
- Lantheus Holdings, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $637.00K.
- Lantheus Holdings, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $0.00.
- Lantheus Holdings, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Lantheus Holdings, Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $692.00K.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 3 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 6 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 9 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month |
|---|---|---|---|---|
| 2025-12-31 | $637.00K 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $692.00K 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$200.00K derived: sum of 2 quarters · filed 2024-02-22 | $0.00 derived: sum of 3 quarters · filed 2024-02-22 | $0.00 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $200.00K derived: sum of 2 quarters · filed 2021-11-04 | $200.00K 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $200.00K 10-Q · filed 2021-07-28 | $200.00K 10-Q · filed 2021-07-28 | ||
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 | |||
| 2018-12-31 | $74.00K 10-K · filed 2020-02-25 | |||
| 2017-12-31 | $69.00K 10-K · filed 2019-02-20 | |||
| 2016-12-31 | $416.00K 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-26 | |||
| 2014-12-31 | $416.00K 10-K · filed 2017-02-23 | |||
| 2013-12-31 | $763.00K 10-K · filed 2016-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |